Company Filing History:
3 out of 6 
1 out of 3,540 
Years Active: 2025
Title: Innovations of Inventor Xin Yao
Introduction
Xin Yao is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of biomedical engineering, particularly in the development of chimeric antigen receptors. With a total of 4 patents, his work focuses on innovative solutions for treating autoimmune disorders and cancer.
Latest Patents
One of Xin Yao's latest patents is titled "Bispecific chimeric antigen receptors targeting CD20 and BCMA." This invention provides a novel approach by combining an scFv targeting CD20 and an scFv targeting BCMA, along with a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. These chimeric antigen receptors can be utilized in the treatment of autoimmune disorders or cancer. Another significant patent is "Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof." This invention includes a combined chimeric antigen receptor that targets both CD19 and CD20, demonstrating high efficacy in killing tumor cells. The invention also encompasses a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, along with applications for CAR-T cells.
Career Highlights
Xin Yao has worked with prominent organizations such as Abelzeta Inc. and the National Institutes of Health, which is a component of the US Department of Health & Human Services. His experience in these institutions has contributed to his expertise in the field of chimeric antigen receptors and their applications in medicine.
Collaborations
Xin Yao has collaborated with notable colleagues, including Yihong Yao and Jiaqi Huang. Their combined efforts have further advanced the research and development of innovative therapies in the biomedical sector.
Conclusion
Xin Yao's contributions to the field of biomedical engineering through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in the treatment of serious health conditions.